Royalty Pharma (RPRX) stock Forecast for 2022 – 2026
Last update: November 27, 2022 (05:19)
Sector: HealthcareThe share price of Royalty Pharma plc (RPRX) now
What analysts predict: $54.35
52-week high/low: $44.45 / $35.67
50/200 Day Moving Average: $41.73 / $41.3
This figure corresponds to the average price over the previous 50/200 days. For Royalty Pharma stocks, the 50-day moving average is the support level today.
For Royalty Pharma stocks, the 200-day moving average is the support level today.
Are you interested in Royalty Pharma plc stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the Royalty Pharma stock price in 2022, 2023, 2024, 2025, 2026. How much will one Royalty Pharma share be worth in 2022 - 2026?
When should I take profit in Royalty Pharma stock? When should I record a loss on Royalty Pharma stock? What are analysts' forecasts for Royalty Pharma stock? What is the future of Royalty Pharma stock? We forecast Royalty Pharma stock performance using neural networks based on historical data on Royalty Pharma stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
Royalty Pharma stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2022, 2023, 2024, 2025 and 2026) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for Royalty Pharma shares. This happens once a day.
Historical and forecast chart of Royalty Pharma stock
The chart below shows the historical price of Royalty Pharma stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the Royalty Pharma stock price can be found in the table below.
Long-term forecasts by years.
Royalty Pharma daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Nov 29 | 42.76 | 42.06 | 43.46 | 3.32 |
| Nov 30 | 43.07 | 42.45 | 43.90 | 3.41 |
| Dec 01 | 42.77 | 41.73 | 43.37 | 3.94 |
| Dec 02 | 42.28 | 41.49 | 42.64 | 2.77 |
| Dec 03 | 43.01 | 42.65 | 43.85 | 2.81 |
| Dec 04 | 44.12 | 43.28 | 44.82 | 3.56 |
| Dec 05 | 44.32 | 43.85 | 44.90 | 2.39 |
| Dec 06 | 44.97 | 44.54 | 45.71 | 2.62 |
| Dec 07 | 46.20 | 45.33 | 46.66 | 2.94 |
| Dec 08 | 45.75 | 45.30 | 46.63 | 2.94 |
| Dec 09 | 45.24 | 44.42 | 45.82 | 3.16 |
| Dec 10 | 46.28 | 45.47 | 46.80 | 2.93 |
| Dec 11 | 46.80 | 46.23 | 47.43 | 2.59 |
| Dec 12 | 47.27 | 46.37 | 47.87 | 3.23 |
| Dec 13 | 47.54 | 46.32 | 48.12 | 3.88 |
| Dec 14 | 49.03 | 47.88 | 49.39 | 3.15 |
| Dec 15 | 49.56 | 48.53 | 50.36 | 3.76 |
| Dec 16 | 50.69 | 50.37 | 51.40 | 2.06 |
| Dec 17 | 49.42 | 48.21 | 50.50 | 4.76 |
| Dec 18 | 49.09 | 48.09 | 50.13 | 4.25 |
| Dec 19 | 48.73 | 48.25 | 49.78 | 3.17 |
| Dec 20 | 47.59 | 47.06 | 48.32 | 2.69 |
| Dec 21 | 47.33 | 46.74 | 48.00 | 2.69 |
| Dec 22 | 48.61 | 47.73 | 49.59 | 3.88 |
| Dec 23 | 48.29 | 47.20 | 48.99 | 3.80 |
| Dec 24 | 49.19 | 48.81 | 50.06 | 2.55 |
| Dec 25 | 49.13 | 48.28 | 50.37 | 4.33 |
| Dec 26 | 49.52 | 48.70 | 50.03 | 2.73 |
| Dec 27 | 49.55 | 48.30 | 50.52 | 4.60 |
| Dec 28 | 50.23 | 49.40 | 50.59 | 2.41 |
Royalty Pharma Daily Price Targets
Royalty Pharma Stock Forecast 11-29-2022.
Forecast target price for 11-29-2022: $42.76.
Negative dynamics for Royalty Pharma shares will prevail with possible volatility of 3.212%.
Pessimistic target level: 42.06
Optimistic target level: 43.46
Royalty Pharma Stock Forecast 11-30-2022.
Forecast target price for 11-30-2022: $43.07.
Positive dynamics for Royalty Pharma shares will prevail with possible volatility of 3.297%.
Pessimistic target level: 42.45
Optimistic target level: 43.90
Royalty Pharma Stock Forecast 12-01-2022.
Forecast target price for 12-01-2022: $42.77.
Negative dynamics for Royalty Pharma shares will prevail with possible volatility of 3.787%.
Pessimistic target level: 41.73
Optimistic target level: 43.37
Royalty Pharma Stock Forecast 12-02-2022.
Forecast target price for 12-02-2022: $42.28.
Negative dynamics for Royalty Pharma shares will prevail with possible volatility of 2.697%.
Pessimistic target level: 41.49
Optimistic target level: 42.64
Royalty Pharma Stock Forecast 12-03-2022.
Forecast target price for 12-03-2022: $43.01.
Positive dynamics for Royalty Pharma shares will prevail with possible volatility of 2.731%.
Pessimistic target level: 42.65
Optimistic target level: 43.85
Royalty Pharma Stock Forecast 12-04-2022.
Forecast target price for 12-04-2022: $44.12.
Positive dynamics for Royalty Pharma shares will prevail with possible volatility of 3.434%.
Pessimistic target level: 43.28
Optimistic target level: 44.82
RPRX (RPRX) Monthly Stock Prediction for 2022
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Dec. | 44.57 | 43.23 | 45.91 | 5.84 |
Royalty Pharma forecast for this year
Royalty Pharma Stock Prediction for Dec 2022
An uptrend is forecast for this month with an optimal target price of $44.5724. Pessimistic: $43.23. Optimistic: $45.91
Royalty Pharma (RPRX) Monthly Stock Prediction for 2023
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 44.67 | 42.95 | 47.04 | 8.71 |
| Feb | 45.39 | 43.83 | 46.66 | 6.06 |
| Mar | 44.85 | 43.62 | 46.01 | 5.19 |
| Apr | 44.06 | 43.35 | 45.69 | 5.13 |
| May | 45.48 | 44.56 | 47.93 | 7.04 |
| Jun | 47.48 | 46.42 | 48.88 | 5.03 |
| Jul | 48.32 | 46.35 | 49.09 | 5.58 |
| Aug | 47.00 | 44.86 | 47.69 | 5.93 |
| Sep | 50.02 | 47.22 | 52.58 | 10.19 |
| Oct | 48.59 | 46.99 | 50.87 | 7.62 |
| Nov | 49.78 | 47.06 | 52.57 | 10.47 |
| Dec | 48.18 | 45.85 | 49.83 | 7.99 |
Royalty Pharma (RPRX) Monthly Stock Prediction for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 49.89 | 48.11 | 51.71 | 6.96 |
| Feb | 52.72 | 49.92 | 55.57 | 10.16 |
| Mar | 53.54 | 52.45 | 55.56 | 5.60 |
| Apr | 55.11 | 53.30 | 56.65 | 5.92 |
| May | 53.68 | 51.65 | 55.07 | 6.21 |
| Jun | 55.71 | 54.15 | 57.35 | 5.58 |
| Jul | 54.81 | 53.43 | 57.35 | 6.82 |
| Aug | 53.36 | 51.30 | 55.56 | 7.66 |
| Sep | 53.95 | 52.44 | 54.71 | 4.14 |
| Oct | 54.11 | 51.98 | 56.72 | 8.35 |
| Nov | 57.21 | 55.37 | 59.45 | 6.87 |
| Dec | 56.65 | 55.58 | 58.63 | 5.21 |
Royalty Pharma (RPRX) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 55.62 | 53.24 | 56.67 | 6.05 |
| Feb | 54.14 | 52.97 | 55.09 | 3.85 |
| Mar | 51.30 | 49.07 | 53.13 | 7.64 |
| Apr | 48.42 | 47.75 | 49.27 | 3.10 |
| May | 49.10 | 47.73 | 51.41 | 7.15 |
| Jun | 46.83 | 45.52 | 48.64 | 6.40 |
| Jul | 46.60 | 45.04 | 47.81 | 5.80 |
| Aug | 48.73 | 47.29 | 50.09 | 5.58 |
| Sep | 50.19 | 47.56 | 52.19 | 8.89 |
| Oct | 49.84 | 48.62 | 50.54 | 3.80 |
| Nov | 49.07 | 47.91 | 50.52 | 5.17 |
| Dec | 50.21 | 49.08 | 51.65 | 4.97 |
Royalty Pharma (RPRX) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 50.28 | 49.50 | 52.95 | 6.51 |
| Feb | 53.76 | 51.54 | 55.49 | 7.12 |
| Mar | 50.19 | 47.59 | 50.92 | 6.55 |
| Apr | 47.55 | 45.49 | 48.62 | 6.44 |
| May | 47.45 | 45.36 | 49.98 | 9.24 |
| Jun | 48.05 | 46.10 | 49.06 | 6.03 |
| Jul | 50.40 | 49.24 | 52.49 | 6.18 |
| Aug | 53.40 | 50.94 | 54.41 | 6.39 |
| Sep | 53.78 | 52.31 | 55.62 | 5.96 |
| Oct | 56.00 | 53.80 | 57.17 | 5.90 |
| Nov | 54.16 | 51.24 | 55.37 | 7.46 |
| Dec | 53.21 | 51.75 | 55.37 | 6.53 |
Royalty Pharma information and performance
Royalty Pharma plc is a biopharmaceutical royalty purchaser and innovation sponsor for the US biopharmaceutical industry. He is also involved in identifying, evaluating and obtaining royalties for various biopharmaceuticals. In addition, the company partners with innovators from academic institutions, research hospitals and non-profit organizations, small and medium-sized biotech companies, and pharmaceutical companies.
110 EAST 59TH STREET, NEW YORK, NY, US
Market capitalization is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of shares in the company outstanding by the market price of one share.
EBITDA is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Royalty Pharma (RPRX) stock dividend
Royalty Pharma last paid dividends on 11/17/2022. The next scheduled payment will be on 12/15/2022. The amount of dividends is $0.74 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Factor:
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.